Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis

Inflammatory Bowel Disease

Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients

doi: 10.1093/ibd/izy358.

Inflammatory Bowel Disease

Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials

Clin Gastroenterol Hepatol.

Cheng D, Cushing KC, Cai T, Ananthakrishnan AN

doi: 10.1016/j.cgh.2020.04.070.

Inflammatory Bowel Disease

Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study

Aliment Pharmacol Ther.

Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, Ungaro R, Sy W, Owen SC, Patel A, Cohen BL, Ananthakrishnan AN

doi: 10.1111/apt.15177.

Inflammatory Bowel Disease

No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: a Meta-Analysis

Clin Gastroenterol Hepatol.

Yzet C, Diouf M, Singh S, Brazier F, Turpin J, Nguyen-Khac E, Meynier J, Fumery M

doi: 10.1016/j.cgh.2020.06.071.

Inflammatory Bowel Disease

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review

BMC Gastroenterol.

Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, Kempf C, Knop J, Campbell-Hill S, Ehehalt R

doi: 10.1186/s12876-020-01332-w.

Inflammatory Bowel Disease

Small Bowel Healing Detected by Endoscopy in Patients With Crohn's Disease After Treatment With Antibodies Against Tumor Necrosis Factor.

Clin Gastroenterol Hepatol.

Takenaka K, Fujii T, Suzuki K, Shimizu H, Motobayashi M, Hibiya S, Saito E, Nagahori M, Watanabe M, Ohtsuka K

doi: 10.1016/j.cgh.2019.08.024.

Inflammatory Bowel Disease

Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status

Clin Gastroenterol Hepatol

Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE

doi: 10.1016/j.cgh.2021.02.043

Early Initiation of Tumor Necrosis Factor Antagonist-based Therapy for Patients with Crohn's Disease Reduces Costs Compared With Late Initiation

Clin Gastroenterol Hepatol.

Beilman CL, Kirwin E, Ma C, McCabe C, Fedorak RN, Halloran B

doi: 10.1016/j.cgh.2018.07.032.

Inflammatory Bowel Disease

No Superiority of Tacrolimus Suppositories vs Beclomethasone Suppositories in a Randomized Trial of Patients With Refractory Ulcerative Proctitis

Clin Gastroenterol Hepatol.

Lie MRKL, Kreijne JE, Dijkstra G, Löwenberg M, van Assche G, West RL, van Noord D, van der Meulen-de Jong AE, Oldenburg B, Zaal RJ, Hansen BE, de Vries AC, van der Woude CJ, Dutch Initiative on Crohn and Colitis (ICC).

doi: 10.1016/j.cgh.2019.09.049.

Related content

Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients

Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials

Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study

No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: a Meta-Analysis

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review

Small Bowel Healing Detected by Endoscopy in Patients With Crohn's Disease After Treatment With Antibodies Against Tumor Necrosis Factor.

Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status

Early Initiation of Tumor Necrosis Factor Antagonist-based Therapy for Patients with Crohn's Disease Reduces Costs Compared With Late Initiation

No Superiority of Tacrolimus Suppositories vs Beclomethasone Suppositories in a Randomized Trial of Patients With Refractory Ulcerative Proctitis